180 related articles for article (PubMed ID: 38307935)
1. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
[TBL] [Abstract][Full Text] [Related]
2. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
3. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
[TBL] [Abstract][Full Text] [Related]
4. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
5. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
6. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
Van Emmenis L; Ku SY; Gayvert K; Branch JR; Brady NJ; Basu S; Russell M; Cyrta J; Vosoughi A; Sailer V; Alnajar H; Dardenne E; Koumis E; Puca L; Robinson BD; Feldkamp MD; Winkis A; Majewski N; Rupnow B; Gottardis MM; Elemento O; Rubin MA; Beltran H; Rickman DS
Cancer Res Commun; 2023 Aug; 3(8):1447-1459. PubMed ID: 37546702
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
8. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
9. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
12. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
[TBL] [Abstract][Full Text] [Related]
13. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
[TBL] [Abstract][Full Text] [Related]
14. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
15. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
17. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
18. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S; Alabi BR; Yin Q; Stoyanova T
Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
[TBL] [Abstract][Full Text] [Related]
20.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
